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statistically significant decrease in reactive oxygen species 
production accompanied by an increase in mitochondrial 
membrane potential and a decrease in oxygen consumption 
compared to 147 ng/mL acetylcholine. The M1 muscarinic 
receptor was involved in these effects. Finally, the involve-
ment of ERK/mitogen-activated protein kinases (MAPK) and 
KI67 confirmed the effectiveness of the single treatment on 
cell proliferation. The intracellular pathways of calcium were 
investigated as well. Our results indicate for the first time 
that highly diluted and kinetically activated acetylcholine 
seems to play an active role in an in vitro model of wound 
healing. Moreover, the administration of acetylcholine with-
in the physiological range may not only be effective but is 
also likely to be safe.  © 2016 S. Karger AG, Basel 
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 Abstract 
 The physiological effects of acetylcholine on keratinocytes 
depend on the presence of nicotinic and muscarinic recep-
tors. The role of nonneuronal acetylcholine in keratinocytes 
could have important clinical implications for patients with 
various skin disorders such as nonhealing wounds.  In order 
 to evaluate the efficacy of highly diluted acetylcholine solu-
tions obtained by sequential kinetic activation, we aimed to 
investigate the effects of these solutions on normal human 
keratinocytes. Two different concentrations (10 fg/mL and
1 pg/mL) and formulations (kinetically activated and nonki-
netically activated) of acetylcholine were used to verify kera-
tinocyte viability, proliferation, and migration and the intra-
cellular pathways involved using MTT, crystal violet, wound 
healing, and Western blot compared to 147 ng/mL acetyl-
choline. The activated formulations (1 pg/mL and 10 fg/mL) 
revealed a significant capacity to increase migration, cell vi-
ability, and cell proliferation compared to 147 ng/mL acetyl-
choline, and these effects were more evident after a single 
administration. Sequential kinetic activation resulted in a 
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Abbreviations used in this paper
Ach acetylcholine
Chel chelerythrine
KC keratinocytes
MAPK mitogen-activated protein kinases
NHEK normal human epidermal keratinocytes
NO SKA nonsequential kinetic activation
ROS reactive oxygen species
SKA sequential kinetic activation
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2
 Introduction 
 Keratinocytes (KC) are the main component of the 
stratified epithelium enveloping the human body. KC 
functions, such as viability, proliferation, and migration, 
depend on a fine balance in control pathways in which the 
nonneuronal cholinergic system plays a major role [Kurzen 
et al., 2007]. This system acts by means of acetylcholine 
(Ach) and its nicotinic and muscarinic receptors via auto-
crine and paracrine mechanisms. Ach is an example of 
phylogenetically old molecules present in a wide range of 
living organisms ranging from prokaryotic to eukaryotic 
neuronal and nonneuronal cells. To date, studies on the 
biological role of Ach have mainly focused on its neu-
rotransmitter function only, although this messenger is 
widely expressed and linked to basic nonneuronal cell 
functions [Wessler et al, 2003; Kurzen et al., 2007; Wessler 
and Kirkpatrick, 2008; Sato et al., 2010; Beckmann and 
Lips, 2013].
 Ach is a crucial regulatory molecule for the skin since it 
has been demonstrated that normal human KC are able to 
synthesize, secrete, and degrade it [Grando et al., 1993]. 
The physiologic regulation of KC exerted by Ach depends 
on the presence of both types of cholinergic receptors, i.e., 
nicotinic and muscarinic, and on competitive or synergic 
interactions with one another. Hence, a single cytotrans-
mitter, either Ach or a cholinergic drug, may exert differ-
ential effects on KC at different stages of their maturation 
[Grando et al., 2006]. Several important functions, includ-
ing control of cell viability, proliferation, adhesion, migra-
tion, and differentiation, have been also attributed to mus-
carinic receptors in KC [Beck et al., 2006]. Simultaneous 
stimulation of nicotinic and muscarinic receptors by Ach 
may be necessary to synchronize and balance ionic and 
metabolic events within cells. In KC, binding of Ach to the 
cell membrane simultaneously elicits several distinct bio-
chemical events, the ‘‘biologic sum” of which, added to the 
effects of other hormonal and environmental stimuli, de-
termines the change in cell behavior during epidermal 
turnover [Grando et al., 1993, 2006]. In recent years, a 
number of studies have clarified the molecular mecha-
nisms underlying skin trophism in order to identify new 
therapeutic strategies for skin diseases. Furthermore, some 
evidence is available about the therapeutic capability of 
cholinomimetics or blockers in two important skin dis-
eases, i.e., pemphigus or psoriatic lesions [Grando et al., 
1993, 2006]. Thus, studying the role of nonnervous Ach in 
KC development and functions could have important clin-
ical implications for patients with several skin disorders 
such as nonhealing wounds or immune and inflammatory 
diseases. In addition, under pathological conditions, tissue 
levels of Ach in skin biopsies are greatly increased [Wessler 
et al., 2003]. It was recently demonstrated in human KC 
that highly diluted carbachol is able to increase transcrip-
tion of matrix metalloproteinase MMP-3 as well as several 
ligands of the epidermal growth factor family [Gariboldi et 
al., 2009], both important factors involved in epidermal 
cell proliferation and wound repair. However, in terms of 
a therapeutic application of Ach, it must be considered that 
this is a highly reactive molecule and consequently its use 
can lead to side effects [Beck et al., 2006]. A promising way 
to obtain a fine regulation of physiological mechanisms 
could be the use of highly diluted substances as been dem-
onstrated by several studies available in the literature. For 
example, recently, evidence of the efficacy of a highly di-
luted form (defined low doses) of IL-12 in modulation of 
Th1 versus Th2 was demonstrated in an asthma preclinical 
model [Gariboldi et al., 2009], suggesting a novel therapeu-
tic approach to diseases which involve a Th1/Th2 imbal-
ance. Moreover, it has been observed that low doses of IL-
12 modulate T-cell subpopulations in cultures of lung can-
cer cells. The same doses of IL-12 also promote inhibition 
of the proliferation of lung adenocarcinoma cells in vitro 
 [D’Amico et al., 2012]. Also, these highly diluted forms 
have been obtained via a sequential kinetic activation 
(SKA) technique and these cytokines have shown capabil-
ity to exert immunomodulatory action in colon cancer as 
well [Radice et al., 2014; Roberti et al., 2014]. Lastly, these 
highly diluted SKA cytokines have been demonstrated to 
have a significant beneficial effect in skin diseases both in 
patients and in cultured cells [Barygina et al., 2015; Radice 
et al., 2015].
 Thus, the aim of this study is to evaluate the effects of 
highly diluted Ach solutions obtained by SKA on cultured 
normal human KC and on an in vitro incisional wound 
model in order to confirm the hypothesis that a highly di-
luted form (defined as “low dose”) of Ach could be a great-
er physiological stimulus for KC viability and proliferation.
 Materials and Methods 
 Preparation of Ach Solutions 
 All dilutions were prepared starting from a stock solution 
(0.001 mg/mL) of Ach (Sigma-Aldrich; Saint Louis, MO, USA) in 
0.9% NaCl. Based on previous knowledge of activated blends 
[Brod and Khan, 1996; Avvakumov et al., 1999], Ach solutions 
were prepared at 2 different concentrations: 10 fg/mL and 1 pg/
mL. Each concentration was prepared using or not using the SKA 
method. The activated solutions, following dilutions, were kineti-
cally energized by a mechanically applied force via a standardized 
shaking process called SKA; the applied shaking procedure is char-
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3
acterized by vertical shaking, a 10-cm motion range, and a shaking 
speed corresponding to 100 oscillations in 10 s. All solutions were 
prepared by GUNA Laboratories (GUNA S.p.a, Milan, Italy).
 For each treatment, the volume of each solution was calculated 
by comparing the volume added to the sample treated with 147 ng/
mL Ach (corresponding to a concentration of 1 μ M ).
 Cell Culture 
 Normal human epidermal keratinocytes (NHEK) from neona-
tal foreskin were purchased from Lonza (Basel, Switzerland) and 
cultured in KBM medium (Lonza) containing KGM-2 (keratino-
cyte growth medium-2) growth supplements (Lonza) in an incu-
bator at 37   °   C, 5% CO 2 , and 95% humidity [Seo et al., 2012]. Ex-
periments were conducted at passages 3–6.
 Experimental Protocol 
 The cells (1 × 10 3 ) were plated on 96-well plates for the MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
test and crystal violet staining; 5 × 10 4 cells were plated on 24-well 
plates to analyze reactive oxygen species (ROS) production; 4 × 10 4 
cells were plated in black 96-well plates to study oxygen consump-
tion and mitochondrial membrane potential; wound healing assay 
and Western blot were performed in 6-well plates until confluence 
to analyze the intracellular pathways.
 The cells were treated with different preparations of Ach [Ach 
SKA 10 fg/mL, Ach SKA 1 pg/mL, Ach nonsequential kinetic acti-
vation (NO SKA) 10 fg/mL, and Ach NO SKA 1 pg/mL] compared 
to 147 ng/mL Ach, a nonactivated form used only as a positive 
control at the concentration reported in the literature [Metzen et 
al., 2003]. The protocol of treatment was divided into 2 steps. In 
the first step, the cells were treated at T0, checked every 24 h, and 
maintained for 144 h (protocol A); in the second step, the cells were 
treated every 24 h, checked every 24 h, and maintained for 144 h 
(protocol B). We also tested in protocol A the involvement of mus-
carinic receptors and calcium using a specific antagonist, treating 
cells 30 min before stimulation; in particular, for muscarinic recep-
tor 1 we used atropine (7.25 μg/mL; Sigma, Milan, Italy) [Kühne 
et al., 2015] and for calcium we used H89 (519 ng/mL, inhibitor of 
PKA kinase; Sigma) and chelerythrine (384 ng/mL, inhibitor of 
PKC kinase; Cayman Chemicals, Cabru, Milan, Italy) [Chernyavsky 
et al., 2009; Cappellano et al., 2013].
 MTT Test 
 After each stimulation, the NHEK were washed with PBS 1× 
and incubated with DMEM without red phenol and FBS contain-
ing 1% MTT dye (MTT-Based In Vitro  Toxicology Assay Kit; Sig-
ma-Aldrich) for 2 h at 37  °  C and 5% CO 2 [Uberti et al., 2011]. Cell 
viability was determined by measuring absorbance using a spec-
trometer (VICTORX4 multilabel plate reader) at 570 nm with cor-
rection at 690 nm and calculated by comparing the results to con-
trol cells (100% viable).
 Crystal Violet 
 After each treatment the cells were fixed with 1% glutaralde-
hyde (Sigma-Aldrich) for 15 min at room temperature, washed, 
and stained with 100 μL 0.1% aqueous crystal violet (Sigma-
Aldrich) for 20 min at room temperature. One hundred micro-
liters of 10% acetic acid were added to multiwell plates and mixed 
before reading the absorbance at 595 nm using a spectrometer 
(VICTORX4 multilabel plate reader). The estimated number was 
calculated by comparing the results to the control cells (control 
T0), examined on the first treatment, and the variation of the un-
treated cells, checked every 24 h (control), was also reported.
 ROS Production 
 The rate  of superoxide anion release was measured using a 
standard protocol based on reduction of cytochrome C [Uberti et 
al., 2014]. In both treated and untreated cells, 100 μL cytochrome 
C were added and in another sample 100 μL superoxide dismutase 
were also added for 30 min in an incubator (all substances were 
from Sigma-Aldrich). The absorbance in culture supernatants was 
measured at 550 nm using a spectrometer (VICTORX4 multilabel 
plate reader) and O 2 was expressed as the mean ± SD (%) of nano-
moles per reduced cytochrome C per microgram of protein com-
pared to the control [Sun et al., 2005].
 Oxygen Consumption and Mitochondrial Membrane Potential 
 In living NHEK plated and treated as previously described, the 
oxygen consumption and mitochondrial membrane potential 
were immediately measured simultaneously following the manu-
facturer’s instructions using an Oxygen Consumption/Mitomem-
brane Potential Dual Assay Kit (Cayman Chemical Company; Ann 
Arbor, MI, USA). The fluorescence of oxygen consumption was 
measured by excitation and emission wavelengths at 380 and 650 
nm, respectively, and the membrane potential was measured using 
JC-1 red aggregates at an excitation/emission of 650/690 nm and 
green monomers at an excitation/emission of 485/535 nm in a flu-
orescence spectrometer (VICTORX4 multilabel plate reader). The 
results are expressed as means ± SD (%) compared to control cells.
 Cell Scratch Wounding Assay 
 A scratch wound healing assay was performed as previously 
described [Liang et al., 2007] in confluent monolayer cells using a 
sterile p200 pipette tip. Afterwards, the cells were stimulated with 
different Ach preparations and physiological saline buffer in dif-
ferent protocols (A and B) and monitored every 24 h for 144 h. 
After each time point, repopulation of the wounded areas was ob-
served under a phase contrast microscope (Leica, Germany). In 
addition, some experiments were performed following protocol A 
only to determine the effects of the blockers during wound healing. 
Using the ImageJ image-processing program, the size of the de-
nuded area was determined at each time point from digital images 
taken at 6 different areas. The results are expressed as means ± SD 
(%) of migrated cells.
 Western Blot 
 After the stimulation cells at confluence were lysed in ice with 
complete tablet buffer (Roche) supplemented with 2 m M sodium 
orthovanadate, 30 μg proteins from each lysate were loaded onto 
10 or 5% SDS-PAGE gels, and PVDF (polyvinylidene difluoride) 
membranes (GE Healthcare Europe GmbH; Milan, Italy) were in-
cubated overnight at 4   °   C with anti-KI67 (1: 500; Santa Cruz, CA, 
USA), anti-phospho-p44/42 mitogen-activated protein kinase 
(MAPK) (p-ERK) (1: 1,000; Euroclone, Milan, Italy), anti-p44/42 
MAPK (ERK1/2) (1: 1,000; Euroclone), anti-M1 receptor (1: 250; 
Santa Cruz, CA, USA), anti-phospho-PKA (1: 250; Santa Cruz, CA, 
USA), and anti PKC (1: 250; Santa Cruz, CA, USA). Protein expres-
sion was normalized to the specific total protein (if possible) and 
verified through β-actin detection (1: 5,000; Sigma-Aldrich) and 
expressed as a mean ± SD (%).
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4
 Statistical Analysis 
 Results are expressed as means ± SD of at least 3 biological 
replicates for each experimental protocol, and each replicate was 
reproduced 3 times for each experimental protocol. Statistical 
comparisons between groups were made using one-way ANOVA 
with Bonferroni’s post hoc test or the Mann-Whitney U test, as 
appropriate, using GraphPad Prism 5 (GraphPad Software, La 
Jolla, CA, USA).  p < 0.05 was considered statistically significant. 
All data from the densitometric analysis were normalized to con-
trol values (defined as 1). All other data from each experimental 
protocol were normalized to control values in percent (defined 
as 0%).
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 Fig. 1. Cell viability and cell counts after 144 h of stimulation with 
different formulations of Ach.  a ,  b Results obtained by MTT and 
crystal violet staining in NHEK treated only at T0 with different 
formulations of highly diluted Ach and maintained for 144 h.  c ,
 d The same agents were added every 24 h for 144 h, and then 
NHEK cell viability and proliferation were measured. The results 
of the MTT test are expressed as means ± SD (%) of 6 biological 
replicates normalized to the control. In the crystal violet evalua-
tion, cell counts are expressed as means ± SD (%) of 6 biological 
replicates.  *    p < 0.05 vs. control.  * *    p < 0.05 vs. 147 ng/mL Ach.
Bars indicate significance between the activated and nonactivated 
forms and between the 2 activated forms. Ach, acetylcholine; SKA, 
sequential kinetic activation; NO SKA, nonsequential kinetic acti-
vation. 
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 Results 
 Proliferation and Cell Viability 
 NHEK cells were treated using 2 protocols (i.e., A and 
B) for 144 h to verify the effects of highly diluted Ach com-
pared to 147 ng/mL Ach on cell viability and proliferation.
 As shown in  Figure 1 a and b, in protocol A, the formu-
lation of sequentially kinetically activated Ach 1 pg/mL 
was able to improve cell viability (48.31 ± 9.4% compared 
to the control) compared to the nonactivated form (29.49 
T0 144 h protocol A 144 h protocol B
Control
Ach
147 ng/mL
Ach SKA
10 fg/mL
Ach NO SKA
10 fg/mL
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 Fig. 2. Involvement of different formulations of Ach in NHEK 
wound closure. On the left are representative pictures of wound 
healing with each treatment at T0, after 144 h in protocol A, and 
after 144 h in protocol B taken through microscopy at an original 
magnification of ×20. Scale bar, 50 μm for all images. On the right, 
the wound closure area calculated by measuring the diminution of 
the wound bed surface by the time using ImageJ software in pro-
tocol A and B is shown. The results are expressed as means ± SD 
(%) of wound closure in 5 biological replicates normalized to each 
T0.  *   p < 0.05 vs. control.  * *   p < 0.05 vs. 147 ng/mL Ach. Bars in-
dicate significance between the activated and nonactivated forms 
and between the 2 activated forms. Ach, acetylcholine; SKA, se-
quential kinetic activation; NO SKA, nonsequential kinetic activa-
tion. 
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6
± 5.05% compared to the control), with 147 ng/mL Ach 
(37.8 ± 7.64% compared to the control) and with sequen-
tially kinetically activated Ach 10 fg/mL (39.74 ± 7.01% 
compared to the control). This effect was statistically sig-
nificant ( p < 0.05) in comparison to untreated cells. This 
increase was also observed with crystal violet staining 
( Fig. 1 b), in which the greater number of counted cells 
was observed with the sequentially kinetically activated 
form of Ach 1 pg/mL (109.6 ± 9.67% compared to the 
control). However, the sequentially kinetically activated 
solutions (Ach SKA 10 fg/mL and Ach SKA 1 pg/mL) 
were able to induce effects similar to those observed on 
cell proliferation using 147 ng/mL Ach (90.8 ± 8.11%; 
109.6 ± 9.67% compared to the control vs. 62.61 ± 10.3% 
compared to the control). On the contrary, in protocol B 
( Fig.  1 c, d) nonsignificant changes in cell viability and 
proliferation were observed in the presence of the sequen-
tially kinetically activated form (Ach SKA 1 pg/mL and 
Ach SKA 10 fg/mL). The maximum effects were observed 
in the presence of nonsequentially kinetically activated 
Ach 10 fg/mL (NO SKA). These results demonstrate the 
importance of dilution and mechanical activation in the 
treatment of cells during the longest period.
 Effects of Activated Ach Solutions on NHEK Migration 
 In this step, the effects of highly diluted Ach in differ-
ent formulations on NHEK migration in a wound healing 
assay were evaluated ( Fig.  2 ). Our results showed in-
creased migration activity ( p < 0.05) in KC treated with 
sequentially kinetically activated Ach 10 fg/mL and 1 pg/
mL (both protocols A and B) compared to the control and 
147 ng/mL Ach, and these effects were more evident in 
the presence of sequentially kinetically activated Ach
1 pg/mL (38 ± 4.92% in protocol A and 15.72 ± 4.12% in 
protocol B) after 144 h of treatment. The group treated 
with nonsequentially kinetically activated Ach 10 fg/mL 
in both protocols showed a greater effect than that treated 
with nonsequentially kinetically activated Ach 1 pg/mL, 
with a maximum effect in protocol A. On the contrary, 
nonsequentially kinetically activated Ach 1 pg/mL was ef-
fective in protocol B only. These data suggest that the se-
quentially kinetically activated solutions of Ach (10 fg/
mL and 1 pg/mL) have an active role in wound closure, 
as shown in  Figure 2 (left).
 Effects of Highly Diluted Ach on ROS Production, 
Mitochondrial Membrane Potential, and Oxygen 
Consumption 
 In NHEK cells treated with 147 ng/mL Ach in both 
protocols an increase in ROS production of about 65.86 
± 7.69% (protocol A) and 67.5 ± 3.54% (protocol B) com-
pared to the control was observed, but in the presence of 
sequentially kinetically activated Ach solutions (10 fg/mL 
and 1 pg/mL) this increase was significantly lower (13 ± 
5.66 and 9.59 ± 2.65% in protocol A, respectively; 10 ± 
1.41 and 8 ± 1.1% in protocol B, respectively) than what 
was observed with 147 ng/mL Ach and with the nonse-
quentially kinetically activated form in both protocols. 
The data are shown in  Figure 3 a and b. These data dem-
onstrate the greater efficacy of the sequentially kinetically 
activated form in terms of normal KC health. As shown 
in  Figure 3 c and d, the activated solutions in both proto-
cols (A and B) were able to increase ( p < 0.05) the mito-
chondrial membrane potential compared to 147 ng/mL 
Ach and the nonsequentially kinetically activated form, 
whereas the maximum effects were observed in the pres-
ence of sequentially kinetically activated Ach 1 pg/mL 
(Ach SKA 1 pg/mL 79.01 ± 3.77% in protocol A and 81.6 
± 4.21% in protocol B compared to the control), indicat-
ing the greater biochemical energy of the cells. In order to 
obtain a more complete description of mitochondrial me-
tabolism and function, an oxygen consumption assess-
ment was also performed. As shown in  Figure 3 e and f, 
the rate of oxygen consumption decreased in all samples, 
indicating physiological activity of the mitochondria, and 
data were inversely proportional to mitochondrial poten-
tial movements ( p < 0.05). It is noteworthy that the se-
quentially kinetically activated solutions (10 fg/mL and
1 pg/mL) induced oxygen consumption similar to that 
observed in samples treated with 147 ng/mL Ach (–18.76 
± 1.38 and –7.49 ± 2.5%, respectively, in protocol A; –3.3 
± 0.61 and –9.08 ± 0.88%, respectively, in protocol B), 
 Fig. 3. ROS production ( a ,  b ), mitochondrial potential membrane 
( c ,  d ), and oxygen consumption ( e ,  f ) in NHEK cells. a ,  b ROS 
production is expressed as means ± SD (%) of 5 biological repli-
cates normalized to control values and indicated as a percentage of 
cytochrome C reduced per microgram of protein with respect to 
the control.  c ,  d Evaluation of the mitochondrial membrane po-
tential in NHEK treated with different formulations of Ach; results 
are reported as means ± SD (%) of 5 biological replicates normal-
ized to control values.  e ,  f Oxygen consumption under the same 
conditions and treatments was assessed. The results are expressed 
as means ± SD (%).  *   p < 0.05 vs. control.  * *   p < 0.05 vs. 147 ng/mL 
Ach. Bars indicate significance between the activated and nonac-
tivated forms and between the 2 activated forms. Ach, acetylcho-
line; SKA, sequential kinetic activation; NO SKA, nonsequential 
kinetic activation. 
(For figure see next page.)
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 Fig. 4. Western blot and densitometric analysis of ERK/MAPK and 
KI67 in NHEK cells.  Protein extracts were analyzed by immuno-
blotting with specific antibodies against the indicated proteins. 
The pictures represent 5 biological replicates for each experimen-
tal protocol (A and B). Data are expressed as means ± SD of 5 bio-
logical replicates for each experimental protocol (A and B).  *   p < 
0.05 vs. control.  * *  p < 0.05 vs. 147 ng/mL Ach. Bars indicate sig-
nificance between the activated and nonactivated form and be-
tween the 2 activated forms. Ach, acetylcholine; SKA, sequential 
kinetic activation; NO SKA, nonsequential kinetic activation. 
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 Fig. 5. Cell viability and proliferation in the 
presence of M1, PKC, and PKA blockers. 
Results obtained by MTT ( a ) and crystal 
violet staining ( b ) in NHEK treated only 
with protocol A. The results are expressed 
as a means ± SD (%) of 4 biological repli-
cates normalized to the control.  *   p < 0.05 
 vs. control.  * *   p < 0.05 vs. atropine 7.25 μg/
mL. Bars indicate significance between the 
activated and nonactivated forms and be-
tween the 2 activated forms in pretreated 
samples. Ach, acetylcholine; SKA, sequen-
tial kinetic activation; NO SKA, nonse-
quential kinetic activation; Chel, chelery-
thrine. 
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10
whereas the nonactivated solutions showed a greater de-
crease in oxygen consumption, thus indicating possible 
stress conditions of the mitochondria.
 Analysis of Intracellular Pathways 
 To investigate the mechanisms activated by highly di-
luted and 147 ng/mL Ach in cell proliferation, NHEK 
cells were treated with the same experimental protocols 
used before. As shown in  Figure 4 , all of these agents were 
able to induce significant changes in the expressions of 
KI67 and ERK/MAPK. In particular, we used the KI67 
protein as a cellular marker to investigate KC prolifera-
tion as KI67 is known to be specifically expressed in nu-
clei of proliferating cells during the cell cycle. As reported 
in Western blot and densitometric analyses ( Fig.  4 ), in 
both protocols sequentially kinetically activated Ach
1 pg/mL was able to induce a significant increase ( p < 
0.05) in KI67 compared to Ach 10 fg/mL and Ach 147 ng/
mL, and these data confirmed the ability of sequentially 
kinetically activated Ach 1 pg/mL to improve cell prolif-
eration in NHEK cells. However, Ach 10 fg/mL also 
showed a significant efficacy, in particular in protocol A, 
in which the increase in KI67 was higher compared to that 
with either 147 ng/mL Ach or the nonsequentially kinet-
ically activated form. In addition, ERK, important mem-
bers of the MAPK family regulating cell migration, were 
evaluated. In both protocols the activated solution of se-
quentially kinetically activated Ach 1 pg/mL was able to 
increase the expression of ERK1/2, and this effect was 
more evident in protocol A compared to what was ob-
served with nonsequentially kinetically activated 147 ng/
mL Ach and sequentially kinetically activated Ach 10 fg/
mL. However, the sequentially kinetically activated Ach 
10 fg/mL solution was more effective than the nonse-
quentially kinetically activated one in inducing phos-
phorylation of ERK/MAPK. This is an important finding 
since ERK phosphorylation acts as a switch for other in-
tracellular pathways and thus is a clear index of cellular 
health. All of these data demonstrate the greater influence 
of the highly diluted Ach on cell proliferation of KC com-
pared to the ponderal Ach concentration.
 Analysis of the Involvement of Muscarinic Receptor 
Subtypes and Calcium Signaling in Effects Induced 
by Ach 
 Since the effects induced by Ach are mediated through 
its muscarinic and nicotinic receptors via the calcium sig-
naling cascade, some of these elements were also analyzed 
during protocol A. In particular, the muscarinic receptor 
subtype 1 (M1) was analyzed. As shown in  Figure 5 , pre-
treatment with atropine at 7.25 μg/mL (M1 inhibitor) was 
able to reduce cell viability and proliferation of NHEK 
cells. In particular, in the presence of different formula-
tions of Ach a significant reduction ( p < 0.05) in the ben-
eficial effects on cell viability and proliferation was ob-
served and this effect was more evident in the presence of 
sequentially kinetically activated Ach 1 pg/mL. In par-
ticular, a decrease of about 40% in cell viability and about 
97% in cell proliferation compared to stimulation with-
out pretreatment was observed.
 In addition, the importance of the involvement of 
the M1 receptor in the mechanism activated by all forms 
of Ach was also clarified by the experiments on wound 
healing, in which pretreatment with atropine at 7.25 μg/
mL significantly reduced the area of closure alone and 
also in the presence of all forms of Ach ( Fig. 6 ). Finally, 
as reported in  Figure 7 , sequentially kinetically activat-
ed Ach 1 pg/mL and 10 fg/mL were able to induce a 
significant increase (Ach SKA,  p < 0.05) compared to 
the control and to the corresponding not-activated 
form in a manner similar to that observed with 147 ng/
mL Ach. In order to verify this effect, NHEK cells were 
pretreated with atropine (7.25 μg/mL) alone and in the 
presence of the different formulations of Ach. This pre-
treatment prevented the activation of M1, and succes-
sive stimulation with different formulations of Ach was 
not able to restore this condition. These data confirm 
the involvement of muscarinic receptor in NHEK cells. 
The downstream signaling from the muscarinic and 
nicotinic classes of Ach receptors involves the second 
messenger pathways that control the expression and ac-
tivity of effector molecules via the common signaling 
cascade Ca 2+ -CamKII-PKC-MEK-ERK. In this context 
 Fig. 6. Involvement of M1, PKC, and PKA blockers in NHEK 
wound closure.  a–d Representative pictures of wound healing with 
each treatment at T0 and after 144 h with protocol A through mi-
croscopy at an original magnification of ×20. Scale bar, 50 μm for 
all microscopy pictures.  e–g Wound closure area; areas were cal-
culated by measuring the decrease in the surface of the bed of the 
wound over time using the ImageJ software (protocol A). The re-
sults are expressed as means ± SD (%) of the wound closure of 4 
biological replicates normalized to each T0.  *  p < 0.05 vs. control. 
 * *  p < 0.05 vs. a specific blocker. Bars indicate significance between 
the activated and nonactivated forms and between the 2 activated 
forms in pretreated samples. Ach, acetylcholine; SKA, sequential 
kinetic activation; NO SKA, nonsequential kinetic activation; 
Chel, chelerythrine. 
(For figure see next page.)
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12
PKC and PKA kinases were also analyzed in NHEK cells 
treated under the same conditions as reported before. 
As shown in  Figure 5 , the specific blockers of PKC (che-
lerythrine at 384 ng/mL) and PKA (H89 at 519 ng/mL) 
were able to prevent any increase in cell viability or cell 
proliferation, maintaining the cell at a basal-like level. 
In the presence of all forms of sequentially kinetically 
activated and nonsequentially kinetically activated Ach, 
these effects were not reverted. These data confirm the 
ability of these blockers to modulate specific intracel-
lular mechanisms as reported in the literature. In addi-
tion, similar data were also observed in wound healing 
experiments in which the blockers prevented the mi-
gration of cells and consequently closure of the lesion 
area. Finally, as shown in  Figure 8 , all of the forms (se-
quentially kinetically activated and nonsequentially ki-
netically activated) and 147 ng/mL Ach were able to in-
duce the activation of PKC and PKA, indicating that 
Ach was able to involve the calcium intracellular path-
way to exert its effects. In particular, 147 ng/mL Ach 
and sequentially kinetically activated Ach 10 fg/mL 
showed similar effects. However, all other formulations 
were able to induce the activation of these kinases ( p < 
0.05) compared to the control. These findings were 
confirmed by the pretreatments with chelerythrine 
(384 ng/mL) and H89 (519 ng/mL) for PKC and PKA, 
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 Fig. 7. Western blot and densitometric 
analysis of the M1 receptor in NHEK cells. 
Protein extracts were analyzed by immu-
noblotting with specific antibodies against 
the indicated proteins. The pictures repre-
sent an example of 3 biological replicates 
for protocol A. Ach, acetylcholine; SKA,
sequential kinetic activation; NO SKA, 
nonsequential kinetic activation. Data are 
expressed as means ± SD of 3 biological 
replicates.  *   p < 0.05 vs. control.  * *   p < 0.05 
vs. 147 ng/mL Ach.  φ   p < 0.05 vs. 7.25 μg/
mL atropine (specific M1 inhibitor). Bars 
indicate significance among the different 
forms of Ach, between activated forms 
alone and in the presence of pretreatment 
with atropine. 
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respectively. These agents were analyzed alone and in 
combination with the different formulations of Ach. As 
evidenced by Western blot and densitometric analysis 
in both of these conditions, stimulation with Ach was 
not effective in inducing activation of the specific ki-
nase. These findings confirm the data observed with 
ERK phosphorylation and demonstrate the great influ-
ence of the highly diluted sequentially kinetically acti-
vated Ach on KC functions.
 Discussion 
 Burn injuries, deep erosions, chronic ulcers, diabetic 
wounds, and graft donor sites are a few of the clinical situ-
ations [Chernyavsky et al., 2012] in which epithelialization 
is uncontrolled or incomplete. In this context, we decided 
to study novel approaches to facilitate epithelialization. In 
the last year, continuously increasing evidence for an ex-
tremely high sensitivity of biological objects to chemical 
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 Fig. 8. Western blot and densitometric analysis of PKC and PKA 
in NHEK cells. Protein extracts were analyzed by immunoblotting 
with specific antibodies against the indicated proteins using also a 
specific antagonist (384 ng/mL chelerythrine and 519 ng/mL H89, 
respectively). The pictures represents an example of 3 biological 
replicates for protocol A. Data are expressed as means ± SD of 3 
biological replicates. Ach, acetylcholine; SKA, sequential kinetic 
activation; NO SKA, nonsequential kinetic activation; Chel, chel-
erythrine.  *    p < 0.05 vs. control.  * *    p < 0.05 vs. 147 ng/mL Ach.
 φ   p < 0.05 vs.  384 ng/mL chelerythrine.  φφ   p < 0.05 vs.  519 ng/mL 
H89.Bars indicate significance among the different forms of Ach, 
between activated forms alone, and in the presence of pretreat-
ment with specific blockers. 
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endogenous effects has been reported [Werkheiser et al., 
2011; Marzotto et al., 2014; Landreneau et al., 2015]. Or-
gans, tissues, and cells are capable of reacting to the pres-
ence of peptides, hormones, and molecular messengers at 
very low concentrations. A pioneering study demonstrated 
that low doses of solutions of mechanically activated IL-12 
and IFN-γ, codelivered via the oral route to experimental 
asthmatic mice, can revert this pathological condition, re-
storing a normal balance between Th1- and Th2-derived 
cytokines and leading the animals to a healthy condition 
[Gariboldi et al., 2009]. Moreover, many clinical trials have 
tested highly diluted SKA drugs in various pathologies. 
Significant effectiveness has been reported in supportive 
therapy and pain relief in cancer patients [Rajendran, 2004; 
Sunila et al., 2009; Radice et al., 2014]. In addition, a reduc-
tion of symptoms and an improved quality of life have been 
observed in patients with psoriasis or vitiligo [Witt et al., 
2009; Roberti et al., 2014; Barygina et al., 2015] or in im-
mune system imbalances [Kho et al., 2012].
 In this work, normal human epithelial KC were used to 
study the effects of highly diluted and mechanically acti-
vated Ach solutions (10 –12 –10 –14 ) in an incisional wound 
model to confirm the hypothesis that low-dose Ach could 
be a more physiological stimulus for KC viability, prolif-
eration, and migration.
 Two different protocols have been used in order to as-
sess the best modality of stimulation of cultured KC. Pro-
tocol A, characterized by a single stimulation, appears to 
be more effective than the protocol with repeated stimula-
tions every 24 h (protocol B) on cell proliferation, viability, 
and migration. We investigated cell proliferation and cell 
migration in different experiments. These two biological 
functions were involved in two important physiological as-
pects of skin regeneration – during the creation of a wound 
the cells migrate and after its closure the cells return to a 
normal turnover. It can be hypothesized that a single stim-
ulation triggers a sequence of intracellular reactions with-
out any negative effect. Moreover, in both protocols low-
dose Ach induced a lower ROS production than high-con-
centration Ach and the control.
 One of the most compelling findings of this work is the 
difference in responses between sequentially kinetically ac-
tivated and nonsequentially kinetically activated Ach solu-
tions, with the former being much more effective than the 
latter. The observation of an increased effect induced by 
mechanical activation of an active principle is not com-
pletely new and has been observed by other authors [Gari-
boldi et al., 2009]. However, in the present work, enhanced 
effects due to mechanical activation have been demon-
strated for the first time within the nonneuronal choliner-
gic system. The mechanisms underlying this increased ef-
fectiveness are still unclear. Here only a mere observation 
of the increased efficacy of sequentially kinetically activat-
ed versus nonsequentially kinetically activated low-dose 
Ach solutions is reported. More research will be necessary 
in the future in order to clarify this aspect.
 Ach is present in all living cells [Hebb, 1962; Grando et 
al., 1993; Fania et al., 2012]. Human skin presents the high-
est concentration of free Ach [Klapproth et al., 1997; Fania 
et al., 2012], which depends on its production and degrada-
tion induced, respectively, by choline acetyltransferase and 
acetylcholinesterase. To exert its effects, Ach binds its mus-
carinic and nicotinic receptors (the muscarinic ones are 
transmembrane glycoproteins applying their function 
through G proteins and leading to activation of the second 
messengers; the nicotinic ones are ligand-gated ion chan-
nels that modify the flow of Na + , Ca 2+ , and K + ) [Fania et 
al., 2012]. The concentrations of Ach used in this study can 
be considered very similar to physiological release from 
human KC. Grando et al. [1993] reported that a single KC 
synthesizes a mean of 2 × 10 –17 moles and releases 7 × 10 –19 
moles Ach/min. This fits very well with the amount of Ach 
administered to cultured cells during the experiments de-
scribed in this work. Data available in the literature show 
significant improvements in mucocutaneous diseases in 
patients who received cholinergic agents as treatment for a 
concurrent disease or owing to the habitual use of nicotine 
products [Kuwahara et al., 2000; Mehta and Martin, 2000]. 
Those reports suggest that cholinergic agents have a huge 
potential for dermatological use.
 Human KC possess cholinergic enzymes for Ach syn-
thesis and degradation [Grando et al., 1993] and are also 
responsive to Ach, believed to act as a local hormone in the 
epidermis [Grando et al., 1993; Beck et al., 2006]. Ach acts 
via the calcium pathway, which funtions as a mediator of 
its effects on the epidermis [Grando et al., 2006] and then 
activates all of the intracellular pathways involved in calci-
um-signaling transduction, including ERK/MAPK [Beck 
et al., 2006; Kühne et al., 2015]. It is important to consider 
the difference in activity which we observed between 147 
ng/mL Ach and sequentially kinetically activated or non-
sequentially kinetically activated forms on proliferation, 
viability, cell migration, ROS production, oxygen con-
sumption, and the mitochondrial membrane potential of 
NHEK. In both protocols (A and B), the sequentially ki-
netically activated Ach 1pg/ml formulation was able to im-
prove cell viability compared to 147 ng/mL Ach and it in-
duced effects similar to those of 147 ng/mL Ach on cell 
proliferation. In a minor manner, similar effects were also 
observed in the presence of sequentially kinetically acti-
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vated Ach 10 fg/mL. Ach 147 ng/mL was chosen as the 
control because it was demonstrated, with a dose-response 
curve, to be the most effective concentration in a similar 
HaCaT (spontaneously transformed aneuploid immortal 
human keratinocyte cell line) experimental model [Metzger 
et al., 2005]. Data described in this work indicate for the 
first time the efficacy of activated low doses of Ach on cell 
culture and demonstrate a minor toxicity compared to 147 
ng/mL. For this reason, low-dose Ach could be important 
for the development of new therapies for nonhealing 
wounds. As a matter of fact, nonhealing wounds are a ma-
jor healthcare problem involving important social and eco-
nomic aspects. Old age, immobility, and repeated trauma 
create conditions for the genesis and maintenance of in-
flammatory processes leading to wound formation. In ad-
dition, metabolic, neurologic, and circulatory factors play 
an important role in wound formation and contribute to 
chronicity. For this purpose, the ability of cells to migrate 
in the presence of the same agents and conditions used be-
fore was also investigated in a wound healing assay model. 
Sequentially kinetically activated forms (1 pg/mL and 10 
fg/mL) revealed a greater capacity for migration compared 
to 147 ng/mL Ach, and these effects were more evident af-
ter a single administration. This is an important element 
because the response to doses of Ach may depend on its 
sensitivity to external perturbations. To verify these benefi-
cial effects on wound closure under physiological condi-
tions, ROS production, oxygen consumption, and mito-
chondrial membrane potential were investigated. Sequen-
tially kinetically activated forms showed a statistically 
significant decrease in ROS production accompanied by 
an increase in mitochondrial membrane potential and de-
creased oxygen consumption in comparison with 147 ng/
mL Ach, indicating the better biochemical energy of the 
cells. Also in this case, protocol A showed greater effects, 
indicating that a single treatment is enough to induce ben-
eficial effects. Finally, the involvement of ERK/MAPK (in-
volved in the regulation of cell migration) and KI67 (ex-
pressed in the nuclei of proliferating cells during the cell 
cycle) in the mechanism activated by Ach confirmed the 
better influence of the single treatment (protocol A) versus 
continuous treatment of the activated low doses on cell 
proliferation compared to 147 ng/mL Ach. Since protocol 
A showed the better efficacy, the other experiments on the 
M1 receptor and the calcium signaling cascade were per-
formed only under this condition. Sequentially kinetically 
activated Ach 1 pg/mL confirmed its higher effectiveness 
compared to the sequentially kinetically activated Ach 10 
fg/mL formulation in M1 receptor, PKC, and PKA activa-
tion. These findings confirm that highly diluted Ach acts 
through the same mechanisms as concentrated Ach and 
support the hypothesis of beneficial effects exerted by low 
doses without any negative effect (e.g., oxidative injury).
 It is noteworthy that, although 147 ng/mL Ach showed 
some efficacy in cell proliferation, it may be harmful to the 
cells due to a significant increase in ROS production.
 Our findings suggest that a single treatment of low dos-
es (10 –12 –10 –14 ) of sequentially kinetically activated Ach 
triggers a cascade of dynamic events that results in better 
regulation of KC functions, cell viability, proliferation, and 
migration. These elements are very important for hypo-
thetical possible fields of application in the clinical setting.
 In conclusion, low doses of sequentially kinetically ac-
tivated Ach seem to play an active role in an  in vitro mod-
el of wound healing. Moreover, these data suggest that ad-
ministration of Ach at doses in a physiological range may 
not only be effective but is also likely to be safe. An intrigu-
ing aspect of this study is with regard to the difference in 
activity that was observed between sequentially kinetically 
activated and nonsequentially kinetically activated solu-
tions, with the former being more effective than nonacti-
vated solutions. The use of activated blends is common in 
different fields, including pharmaceutical technology, to 
obtain a high therapeutic potential with very low dosages.
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